[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Exhibit 10.12.1
March 1, 2002
Xxxxxx X. Xxxxxxxxx, Ph.D.
Director, Technology Transfer & Licensing
DuPont Agriculture & Nutrition
Experimental Station
P.O. Box 80402
Wilmington, DE 19880
Dear Bob:
This letter will serve to confirm and memorialize our agreement to amend,
in certain respects, the Research Collaboration Agreement dated October 29, 1998
(the "Agreement"), by and between you ("DuPont") and Lynx Therapeutics, Inc.
("Lynx"). Unless otherwise defined herein Capitalized Terms used herein shall
have the meanings given to them in the agreement.
With respect to Experiments to be performed by Lynx for DuPont during [ *
], the parties have agreed as follows:
1. Lynx's fees for Experiments performed on samples received by Lynx
during [ * ] will be fixed at $[ * ] per Experiment.
2. Each Experiment that consists of a signature sequencing analyses of a
sample will result in at least [ * ] per Experiment.
3. Pursuant to Section 4.2(a) of the Agreement, and conditioned upon the
delivery by Lynx to DuPont of [ * ], DuPont agrees to pay Lynx [ * ] dollars
within [ * ] business days of receipt of said [ * ], less the amount of any [ *
] that have already been made. For clarity, the said [ * ] payment represents [
* ] payment of the [ * ] each that were to be made in [ * ] pursuant to Section
4.2 (a) of the Agreement for work performed during [ * ]. The above payments
shall be creditable against Lynx's fees for such services. Also, DuPont agrees
to [ * ] the date of the [ * ] U.S. dollar payment that was due by [ * ] under
the Agreement to the new date of no later than [ * ].
4. Except as expressly provided herein, the Agreement shall remain in full
force and effect.
If the foregoing is consistent with DuPont's understanding of our
agreement, please execute the enclosed copy of this letter and return it to
Lynx.
Very truly yours,
Lynx Therapeutics, Inc. Confirmed and Agreed: X.X. xxXxxx de Nemours
Co. and Co. Crop Genetics
Research
By: /s/ Xxxxxx X. Xxxxxx By: /s/ Xxxxx X. Xxxxxx
-------------------------- -----------------------------------------
Xxxxx X. Xxxxxx, Vice President
/s/ Xxxxxx Xxxxxxx Xxxx Genetics Research & Development
By: /s/ Xxxxxx X. Xxxxxxxxx
-----------------------------------------
Xxxxxx X. Xxxxxxxxx, Director
Technology Transfer & Licensing
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
